| Michael F Kaveney, MD | |
|
13914 Southeastern Pkwy, Suite 201, Fishers, IN 46037-7127 | |
| (317) 275-1999 | |
| (317) 275-1945 |
| Full Name | Michael F Kaveney |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery |
| Location | 13914 Southeastern Pkwy, Fishers, Indiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902844749 | NPI | - | NPPES |
| 4389953 | Other | IN | AETNA PIN |
| 100088590 | Medicaid | IN | |
| 000000093732 | Other | IN | ANTHEM PIN |
| 701446 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XX0005X | Orthopaedic Surgery - Sports Medicine | 40514 (Arizona) | Secondary |
| 207X00000X | Orthopaedic Surgery | 01033579 (Indiana) | Primary |
| Entity Name | Sjhmc Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326098005 PECOS PAC ID: 4486646197 Enrollment ID: O20040401001189 |
News Archive
The Italian government has removed the necessity for all children to be vaccinated against 10 important infectious diseases before they can join school or day care. This has shocked and angered the medical and scientific community.
Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the release of its DefineValidator tool, Release 1.0, as a free download for CDISC adopters.
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
Two recent studies are souring milk's image among health authorities. One, published in the November issue of the American Journal of Clinical Nutrition, shows that women who consume two or more glasses of milk a day have twice the risk of a certain form of ovarian cancer than those who rarely or never consume milk.
Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael F Kaveney, MD 13914 Southeastern Pkwy, Suite 201, Fishers, IN 46037-7127 Ph: (317) 275-1999 | Michael F Kaveney, MD 13914 Southeastern Pkwy, Suite 201, Fishers, IN 46037-7127 Ph: (317) 275-1999 |
News Archive
The Italian government has removed the necessity for all children to be vaccinated against 10 important infectious diseases before they can join school or day care. This has shocked and angered the medical and scientific community.
Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the release of its DefineValidator tool, Release 1.0, as a free download for CDISC adopters.
Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.
Two recent studies are souring milk's image among health authorities. One, published in the November issue of the American Journal of Clinical Nutrition, shows that women who consume two or more glasses of milk a day have twice the risk of a certain form of ovarian cancer than those who rarely or never consume milk.
Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
› Verified 5 days ago
Dr. Michael T Thieken, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 10995 Allisonville Rd, #102, Fishers, IN 46038 Phone: 317-915-8110 Fax: 317-915-8120 | |
Kevin A Sonn, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 13100 E 136th St Ste 2000, Fishers, IN 46037 Phone: 317-962-4940 | |
Matthieu Zingg, Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 13000 E 136th St, Fishers, IN 46037 Phone: 804-356-6205 | |
Stephen B Sexson, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7436 Glenvista Pl, Fishers, IN 46038 Phone: 317-845-0889 | |
Dr. Erica Elizabeth Fisk, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 10995 Allisonville Rd Ste 102, Fishers, IN 46038 Phone: 317-915-8110 Fax: 317-915-8120 | |
Leonard T Buller, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 13100 E 136th St Ste 2000, Fishers, IN 46037 Phone: 317-688-5980 Fax: 317-566-2736 | |
Dr. Marc Stuart Zipper, D.O. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 13521 Promise Rd, Fishers, IN 46038 Phone: 317-770-9898 |